FOXO4-DRI
Also known as FOXO4 D-retro-inverso peptide, FOXO4-DRI peptide
A cell-penetrating D-retro-inverso peptide studied preclinically for disrupting FOXO4-p53 interactions in senescent-cell research models.
Overview
FOXO4-DRI is a D-retro-inverso peptide designed to interfere with interactions between FOXO4 and p53 in senescent-cell models. It is one of the more visible experimental peptide ideas in senolytic research.
The Science
The proposed mechanism is selective pressure on senescent cells by altering FOXO4-p53 signaling. That makes it interesting, but it also means the evidence bar is high.
- Senescence biology - cells that persist in a stress-arrested state.
- FOXO4-p53 signaling - proposed target interaction.
- Preclinical aging models - much of the public interest comes from animal and cell data.
Evidence Snapshot
FOXO4-DRI is not an approved anti-aging therapy. It remains a preclinical research compound with major questions around selectivity, delivery, safety, and reproducibility.
Related
More in Longevity
5-Amino-1MQ
Research compoundLongevity
Not a peptideSmall molecule
A small-molecule compound that researchers and self-experimenters study for its effects on metabolism, body composition, cellular energy, and healthy aging. Often discussed as a tool for understanding and potentially optimizing metabolic flexibility through NNMT inhibition.
B12
FDA-approvedLongevity
Not a peptideVitamin
An essential water-soluble vitamin required for red blood cell formation, nervous-system function, DNA synthesis, and one-carbon metabolism; it is not a peptide.
Cardiogen
Research compoundLongevity
A short bioregulator peptide discussed in cardiovascular-aging research traditions, usually represented by the tetrapeptide Ala-Glu-Asp-Arg.